A high-risk patient with early-stage HER2-positive breast cancer treated with extended adjuvant therapy
06 Jan 2025
byDr. Heming Zheng, Specialist in Surgical Oncology & Breast Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, China
A 48-year-old premenopausal female presented in July 2021 with a self-detected nodule in her left breast, which she had noticed 1 week ago. Upon physical examination, a 2 cm mass in the left breast and a 2 cm lymph node (LN) in the left axilla were palpable. Further diagnostic workup revealed an irregular-shaped mass measuring 18 x 12 mm with lobulated edges and an enlarged LN of 24 x 13.9 mm in the left axilla, without distant metastasis. Biopsy of the breast mass showed invasive carcinoma that was HER2-positive, oestrogen receptor (ER)–negative and progesterone receptor (PR)–negative, with a Ki-67 level of 50 percent. The patient was diagnosed with HER2-positive breast cancer (BC; cT1N1M0).